BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury
News | 07. 08. 2015
Thrasos Therapeutics
MONTREAL, July 7, 2015 – Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced the completion of enrollment in its Phase 2 clinical study of THR-184 for the prevention of acute kidney injury (AKI) in “at risk” patients undergoing cardiac surgery. Results from the 452-patient study are expected by January 2016.
